Global pharma chief Hussain joins a long list of departing execs at GSK, Merrimack taps Sanofi Genzyme SVP Dr. Richard Peters as CEO, and ex-GSK rare disease…

Immunomedics says new data for lead drug IMMU-132 in triple-negative breast cancer keep it on course to file for accelerated approval in mid-2017.

In this week's EuroBiotech Report, Evotec co-founds startup, ObsEva sets terms for IPO, U.K. heads for hard Brexit and more.

NYSE-listed small cap PharmAthene and private infectious disease biotech Altimmune have signed a merger pact that will see the pair become one in an all-stock…

The UK BIA has responded with cautious optimism and concerns to the British prime minister’s clearest statement yet on the priorities for Brexit negotiations.

Carlo Russo has joined a growing list of ex-GlaxoSmithKline staffers moving into biotech after working on and helping launch the Big Pharma’s rare disease drug…

Merrimack Pharmaceuticals has lured Dr. Richard Peters from Sanofi Genzyme to serve as its CEO.

GeoVax has partnered with Georgia State University to try to pursue an elusive goal—the development of an effective therapeutic vaccine for hepatitis B virus (…

Eli Lilly says it will spend nearly $1 billion to buy out CoLucid Pharmaceuticals and get its hands on its late-stage acute migraine candidate, and is a case…

Biotech